News
BMY
67.01
+2.35%
1.54
SA Asks: What are the most promising oncology companies right now?
Seeking Alpha · 5h ago
Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' August DiviDogs
Seeking Alpha · 10h ago
Bristol-Myers Squibb Adds Early Alzheimer’s Antibody To Its Long-Term Growth Story
TipRanks · 1d ago
Lawmakers ask FDA to scrutinize Chinese trials amid deaths - report
Seeking Alpha · 1d ago
Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock
NASDAQ · 1d ago
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Revolution Medicines (RVMD) and MDxHealth (MDXH)
TipRanks · 1d ago
Bristol Myers Squibb (BMY) Teams Up On AI Antibody Discovery Push
Simply Wall St · 1d ago
Bristol‑Myers Squibb Advances Navlimetostat Metabolism Study, Signaling Steady Pipeline Progress
TipRanks · 2d ago
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
NASDAQ · 2d ago
Bristol in deal with Chai Discovery to use AI for antibody discovery
Seeking Alpha · 2d ago
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Seeking Alpha · 2d ago
Turn Bristol-Myers Squibb into an Income Machine with This Options Play
Barchart · 2d ago
Is Bristol-Myers Squibb (BMY) Fully Priced As FDA Approval And $2.3b Expansion Lift Outlook?
Simply Wall St · 3d ago
Notable Wednesday Option Activity: WMT, MDT, BMY
NASDAQ · 3d ago
Trump nominates White House adviser Overton as next FDA commissioner
Seeking Alpha · 3d ago
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
Seeking Alpha · 3d ago
The Key to Pharma M&A: Never Shopping Hungry - Heard on the Street
The Wall Street Journal · 3d ago
Trump expected to nominate White House aide Heidi Overton as FDA commissioner
Seeking Alpha · 3d ago
President boasts of drug savings with Most Favored Nation policy, TrumpRx
Seeking Alpha · 4d ago
GSPY, TMUS, BMY, PLD: Large Outflows Detected at ETF
NASDAQ · 4d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).